A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >-12 to <18 Years of Age, and Weigh >-35 kg

Administered By

Awarded By

Contributors

Start/End

  • October 8, 2020 - January 15, 2022